- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01075997
The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus
24 februari 2010 bijgewerkt door: Walter Reed Army Medical Center
The purpose of the study is to determine whether having a video cell phone that gives daily reminders over a 6-month period to check blood surgery and take your diabetes medications can improve your diabetes control during that time and if that benefit lasts for up to 1 year.
Studie Overzicht
Toestand
Onbekend
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The purpose of this study is to determine if a cell phone video reminder system will improve compliance and glycemic control in patients with diabetes mellitus when compared with standard of care.
We plan to partner with Affinity Network, Inc., a local minority-owned small business, to provide broadband-enabled cell phone service to patients with diabetes mellitus.
Their IntelaCare™ system will host the content and transmit it to the phones on a personalized schedule.
This will be a prospective, randomized, controlled trial comparing patients with diabetes mellitus who receive daily video reminders via cell phone to take their medications and check their blood glucose with patients who are just given a cell phone without daily reminders.
The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).
The secondary endpoints will compare mean daily glucose levels, the number of both hypoglycemic and hyperglycemic events, the amount of time spent in target blood glucose, and the perceived level of diabetes-related stress between the two groups.
Patients in both groups will receive a broad-band enabled cell phone and cell phone service for the duration of the study.
Patients will be randomized into a "cell phone" group (group A) and a "cell phone plus reminder" group (group B).
They will be seen by their provider at least quarterly (or more often as clinically appropriate).
Blood glucose readings will be downloaded from patients' glucometers at every provider visit (at least quarterly).
Group B will receive a daily 15-second video from their provider reminding them to take their medication and to test their blood sugar and an educational "tip-of-the day."
These reminders will be personalized and recorded by their provider.
During the second 6 months, the patients will be followed by their provider at least quarterly.
Improvement in glycemic control will be determined by quarterly measurements of A1c and the mean and standard deviation of blood glucose.
In addition, the number of home blood glucose tests performed on a weekly basis will be compared.
Compliance with medication will be determined by pharmacy refill records and pill counts.
Quality-of-life will be measures using 2 validated instruments at 0, 26 and 52 weeks - the Problem Areas in Diabetes (PAID), which is a diabetes-related quality of life questionnaire and the SF-8, which is a general quality of life questionnaire for people with chronic disease.
Studietype
Ingrijpend
Inschrijving (Verwacht)
170
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
District of Columbia
-
Washington DC, District of Columbia, Verenigde Staten, 20307
- Walter Reed Army Hospital Center
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 89 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- age 18 or greater
- A1c greater than 8%
- ability to use a cell phone and glucose meter
- ability to understand English
- on oral therapy and/or insulin
Exclusion Criteria:
- under age 18
- non-English speaking
- females who are pregnant, lactating, planning to become pregnant, or without a safe contraceptive method
- A1c less than 8%
- use of glucocorticoids, amphetamines, anabolic, or weight-reducing agents during the course of the study
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: A cell phone tips
This group will receive a cell phone and cell phone service for 1 year.
This group will receive a daily video reminders and tips for the first 6 months of the study.
For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent.
The group will be instructed on how to use the cell phone.
The group will be asked to check blood sugar on a schedule determined by their providers.
The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed.
The group will have the A1c measured.
Also it will have this test repeated about every 3 months.
They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
|
This group will receive a cell phone and cell phone service for 1 year.
This group will receive a daily video reminders and tips for the first 6 months of the study.
For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent.
The group will be instructed on how to use the cell phone.
Andere namen:
|
|
Actieve vergelijker: B no cell phone tips
This group will receive a cell phone and cell phone service for 1 year.
For the second 6 months this group will be seen by their providers at least every 3 months.
The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider.
The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed.
The group will have A1c measured.
Also it will have this test repeated about every 3 months.
They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
|
This group will receive a cell phone and cell phone service for 1 year.
For the second 6 months this group will be seen by their providers at least every 3 months.
The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider.
The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).
Tijdsspanne: week 0, week 12, week 26, week 38, week 52
|
week 0, week 12, week 26, week 38, week 52
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
To compare mean blood glucose levels,the number of hypo- and hyperglycemic events,the duration of time spent in target blood glucose range,the perceived level of diabetes-related stress and the perceived effect of diabetes on quality of life.
Tijdsspanne: week 0, week 12, week 26, week 38, week 52
|
week 0, week 12, week 26, week 38, week 52
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Amanda Bell, MD, WRAMC
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 november 2007
Primaire voltooiing (Verwacht)
1 juli 2010
Studie voltooiing (Verwacht)
1 oktober 2010
Studieregistratiedata
Eerst ingediend
24 februari 2010
Eerst ingediend dat voldeed aan de QC-criteria
24 februari 2010
Eerst geplaatst (Schatting)
25 februari 2010
Updates van studierecords
Laatste update geplaatst (Schatting)
25 februari 2010
Laatste update ingediend die voldeed aan QC-criteria
24 februari 2010
Laatst geverifieerd
1 juni 2009
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- WU#07-13025
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .